**A RANDOMISED EVALUATION OF LOW-DOSE ARA-C PLUS TOSEDOSTAT VERSUS LOW DOSE ARA-C IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS OF THE LI-1 TRIAL**

Mike Dennis1, Alan Burnett2\*, Robert Hills3, Ian Thomas4, Cono Ariti4, Marianne Tang Severinsen5,6, Claire Hemmaway7, Paul Greaves8, Richard E Clark9, Mhairi Copland2, Nigel Russell10 on behalf of the NCRI AML Working Group

1. Department of Haematology, Christie Hospital NHS Trust, Manchester, UK
2. Paul O’Gorman Leukaemia Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK

3. Nuffield Department of Population Health, University of Oxford, Oxford, U.K

4. Centre for Trials Research, Cardiff University, Cardiff, UK

1. Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark,
2. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
3. Department of Haematology, Auckland City Hospital, Auckland, New Zealand,
4. Department of Haematology, Queen's Hospital, Romford, UK
5. Department of Molecular & Clinical Cancer Medicine, University of Liverpool. UK.
6. Department of Haematology, Nottingham University Hospitals, Nottingham, UK

**Abstract:** 206 words  **Text:** 3453 words

**Corresponding author:**

Dr Mike Dennis

The Christie Hospital

Wilmslow Road

MANCHESTER

 M20 4BX

Tel: 0161 446 3869

Mike.dennis1@nhs.net

\*Formerly Department of Haematology, Cardiff University, Cardiff, U.K.

**Abstract**

Older patients with acute myeloid leukaemia account for nearly half of those with the disease. Because they are perceived to be unfit for, unwilling to receive, or unlikely to benefit from conventional chemotherapy they represent an important unmet need. Tosedostat is a selective oral aminopeptidase inhibitor, which in phase I/II trials showed acceptable toxicity and encouraging efficacy. We report the only randomised study of low dose ara-C (LDAC) combined with tosedostat (LDAC-T) versus LDAC in untreated older patients not suitable for intensive treatment. 243 patients were randomised 1:1 as part of the “Pick a Winner” LI-1 trial. There was a non-significant increase in CR rate with the addition of tosedostat (LDAC-T vs LDAC; 19% vs 12%, OR 0.61 (0.30-1.23) p=0.17). For overall response (CR+CRi), there was little evidence of a benefit to the addition of tosedostat (25% vs 18%; OR 0.68 (0.37-1.27) p=0.22). However overall survival (OS) showed no difference (2-year OS 16% vs 12%, HR 0.97 (0.73-1.28) p=0.8). Exploratory analyses failed to identify any subgroup benefitting from tosedostat. Despite promising pre-clinical, early unrandomised clinical data with acceptable toxicity and an improvement in response, we did not find evidence that the addition of tosedostat to LDAC produced a survival benefit in this group of AML patients.

Trial Reference ISRCTN40571019

**Introduction**

A major current challenge in the treatment of acute myeloid leukaemia (AML) is to find effective, convenient and safe treatment for older patients1,2. Almost half of patients with AML are over 70 years of age. To date, intensive therapy, even for those considered fit enough to receive it, delivers poor survival particularly for patients with co-morbidities, poor performance score or adverse disease biology. Ever since, in the overdue clinical trials in this population, it has been assumed that unless remission was achieved, little benefit was anticipated. Standards of care include low dose ara-C (LDAC)3 and the hypomethylating agents azacitidine4 or decitibine5, each of which have low remission rates, although the hypomethylating agents may prolong survival without achieving remission. Several new treatments tested in this context have substantially improved remission rates, but not overall survival, although the recently published results of combining venetoclax with azacitidine have for the first time prolonged survival in this patient group with a non-intensive approach6

Tosedostat is an example of a new class of orally administered metalloenzyme inhibitors with anti-proliferative and anti-angiogenic activity in vivo and in vitro against a wide range of haematological and solid human cancer cells7. Exposure of cells to tosedostat results in the intracellular accumulation of an acid metabolite, CHR-79888, which exerts a powerful inhibitory effect on intracellular metalloenzymes resulting in anti-proliferative, pro-apoptotic and anti-angiogenic activity8. The intracellular metalloenzyme targets for tosedostat are likely to be members of the M1 family of aminopeptidases, so tosedostat is an aminopeptidase inhibitor. Aminopeptidases play a critical role in the final steps of protein recycling downstream of proteasomal degradation and inhibition of aminopeptidases by tosedostat may, like proteasome inhibition, disrupt the turnover of cellular proteins in such a way that it impacts cancer cell growth9. Natural product inhibitors of aminopeptidases, particularly bestatin, exhibit similar, albeit weaker, pharmacological actions to tosedostat, including its pro- apoptotic, anti-proliferative and anti-angiogenic effects and its ability to induce amino acid deprivation response (AADR) related gene expression changes10.Tosedostat synergises in vitro with a very wide range of chemotherapeutic and targeted agents in inducing anti-proliferative effects in many haematological and non-haematological cancer cell lines. We previously showed evidence of synergy with ara-C in pre-clinical studies with human AML cells11.

A number of early stage clinical trials established a daily dose level of 120mg, with little toxicity and some encouraging clinical activity. The initial phase 1 study defined 180mg as the maximum tolerated dose (MTD) with the limitation being protracted thrombocytopenia, and demonstrated good tolerance at a daily dose of 130mg. In a total of 51 patients with relapse/refractory disease in the study, the overall marrow response was 24%12. A second study, (OPAL)13, also in relapsed/refractory older patients, assessed more prolonged administration at two dose levels (240mg for 2 months then 120mg for 4 months or 120mg for 6 months). Initially 35 patients were allocated to each schedule which resulted in an overall response rate (ORR) of 22%. From this study the dose for prolonged treatment emerged as 120mg once a day. Based on the pre-clinical evidence of synergy Mawad and colleagues14, in a phase 2 study which included 26 untreated older patients combined tosedostat (120mg) daily with conventional dose ara-C (1g/m2 days 1-5) or decitibine (20mg/m2/days 1-5). A subsequent 8 patients received a higher tosedostat dose. Complete remission (CR)/complete remission with incomplete recovery of counts (CRi) CR/CRi was achieved in 53% and it was concluded that the 120mg dose was preferable. Finally Visani and colleagues15 conducted an unrandomised phase II study on 33 older untreated patients with the LDAC and tosedostat combination and showed a CR/CRi rate of 54%, the majority of which were CRs. Of additional interest was that they suggested that those patients who achieved CR could be predicted with a 212 gene panel. A microarray analysis performed in 29 of 33 patients identified 188 genes associated with clinical response (CR vs no CR). Three of them (CD93, GORASP1, CXCL16) were validated by quantitative polymerase chain reaction16.

This potential improvement in efficacy and tolerability suggested that it may be especially relevant in the management of older patients who frequently have resistant disease and tolerate traditional therapies poorly. We therefore investigated whether tosedostat combined with LDAC was superior to LDAC alone as first line therapy for older patients with AML who were not considered fit for intensive therapy.

**Methods.**

This evaluation of tosedostat was a component of our “Pick a Winner” trial strategyin the LI-1 trial (ISRCTN40571019) where patients are randomised between a control arm (LDAC) and one of a number of experimental options17. The comparison is only between each experimental option and LDAC, and not between the experimental options. Patients allocated to LDAC only act as controls to patients who have been contemporaneously randomised to an experimental arm.

Patients were eligible if they had de novo or secondary AML or high risk myelodysplastic syndrome (MDS), defined as >10% marrow blasts, and were older than 60 years and considered unfit for intensive chemotherapy. “Unfitness” was determined by the investigator/attending clinician- not specifically protocol defined and documented by collection of co-morbidity using components of the Sorror index18. Patients with a prior diagnosis of MDS (>10% blasts, RAEB 2) who had received azacitidine were not eligible, but patients with a prior diagnosis of MDS with <10% blasts who have failed a demethylation agent and then developed AML were. Patients were categorised for response and survival using the validated multi-parameter Wheatley risk score19 which predicted survival based on age, performance status, cytogenetics, and de novo or secondary disease. This score has been prospectively validated in older patients treated both non-intensively with LDAC and with intensive chemotherapy. Diagnosis and response definitions described below were designated by the local investigator. Cytogenetics (a minimum of 20 metaphases) and immunophenotypic characterization were carried out in regional reference laboratories which participate in national quality assurance schemes.

In this study patients were randomised 1:1 to LDAC or LDAC combined with tosedostat (LDAC-T). LDAC treatment comprised Ara-C 20mg twice a day for 10 days by subcutaneous injection for 4 courses given at 4 to 6 weeks intervals (there was no placebo). Tosedostat was given orally at 120mg once a day continuously for up to 6 months. Patients who were considered to be benefiting, by demonstrating stable disease or continuing response, were permitted to continue on their allocated treatment.

Patients were required to provide written consent and the trial was sponsored by Cardiff University and approved by the Wales Research Ethics Committee in compliance with the Declaration of Helsinki.

**Endpoints and assessments:** The primary endpoint was overall survival (OS), following international guidelines OS is defined as the time from randomisation to death.The protocol defined complete remission (CR) as a normocellular bone marrow aspirate containing <5% leukaemic blasts and showing evidence of normal maturation of other marrow elements. Persistence of myelodysplastic features did not preclude the diagnosis of CR. To achieve CR, patients required neutrophil recovery to ≥1.0x109/l and also platelets to ≥100x109/l, without evidence of extramedullarydisease.Patients who achieved CR according to the protocol, but without evidence of adequate count recovery are denoted here as CRi, patients were required to be platelet-transfusion independent indicating sufficient time for marrow regeneration. Overall response was defined as CR/CRi as we do not have complete date on partial response and morphologic leukaemia free state. For remitters, relapse free survival (RFS) was the time from remission (CR or CRi) until relapse or death. Survival from CR is defined as the time from CR/CRi (first report) until death.

**Toxicity:** Adverse events and toxicity were recorded as defined by the National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) version 3.

## Statistical methods: All analyses are by intention-to-treat. Categorical endpoints (e.g. CR rates) were compared using Mantel-Haenszel tests, giving Peto odds ratios and confidence intervals. Continuous/scale variables were analysed by non-parametric (Wilcoxon rank sum) tests. Time-to-event outcomes were analysed using the log-rank test, with Kaplan-Meier survival curves. Odds/hazard ratios (OR/HR) less than 1 indicate benefit for the investigational therapy. In the Pick-a-Winner design analyses are performed for each investigational arm separately versus the control arm of LDAC. In addition to overall analyses, exploratory analyses were performed stratified by the randomisation stratification parameters and other important variables, with suitable tests for interaction. Because of the well-known dangers of subgroup analysis, these were interpreted cautiously.

The power calculation for the trial as a whole specified that final analysis was to be performed after 340 events (deaths) had been reported. Under the rules of the “Pick a Winner” design, the data monitoring committee (DMC) initially examined outcomes after response data were available for the first 100 patients in each randomisation (50 patients in each arm). At this point, in order to show sufficient promise to be carried forward, there had to be at least a 2.5% improvement in remission rates (CR+CRi) for the experimental arm over the control arm. At this time, the DMC also assessed survival and toxicity as additional criteria to be satisfied, although there was no formal stopping rule for either of these endpoints. If the DMC believed there was sufficient promise in the arm, the trial would continue to accrue until approximately 100 patients were in each arm. Once 170 deaths had been recorded a further interim analysis was performed and the hazard ratio for survival was required to be less than 0.85 in order for the trial to consider continuing to 400 patients and 340 events. At this point, the decision to stop or continue is made on the basis of the hazard ratio for OS. The aspiration of the study is a doubling of survival from 11% to 22% at two years which is equivalent to an average hazard ratio of 0.69.

At the time of this final analysis the median follow-up for OS is 48 months (range 0.2-40.5). Surviving patients are censored at the date last known to be alive.

**Results:**

**Patient Characteristics:** Between June 2014 and February 2017, 243 patients with a median age of 76 years (range 60-88) entered the randomisation, of whom 60% were male and 40% female. Sixty-six percent had de novo AML, 28% secondary AML, and 6% high risk MDS. Cytogenetic analysis identified 1% had favourable, 65% intermediate and 22% adverse cytogenetics (table1). By the validated Wheatley index19, 5% were good risk, 36% standard risk and 58% poor risk. This validated score would predict an expected 12 month survival of 36%, 42% and 14% for LDAC monotherapy in the three risk groups based on historical data, and would be equivalent to a predicted overall 12-month survival of approximately 25%.

The disposition of the patients is shown in figure 1 (CONSORT diagram). A median of 2 courses (range 1-8) was delivered in either arm. For LDAC-T the mean was 2.9; and number of courses was 0=6%; 1=38%; 2=24%; 3=5%; 4=6%; 5=5%; 6=4%; 7=3%; 8=13%. For LDAC alone, the mean was 2.3, and the number of courses was 0=5%; 1=34%; 2=18%; 3=4%; 4=10%; 5=3%; 6=9%; 7=2%; 8=15%; p= 0.3).

The reasons provided by investigators for not receiving intensive therapy were age in 90% of cases, fitness in 45% of cases (both together in 38% of cases), and other reasons in 5% of cases of which over half were patient choice. The HCT-CI was (0 = 42%, 1-2 = 30%, 3+ =28%). Of the co-morbidities listed on entry, the most frequent were those described as prior tumour (14%), diabetes (13%); cardiac (9%); infection (9%), mild-to-moderate pulmonary (8%); rheumatological (8%); obesity (8%) and arrhythmia (5%) (table 1). No other co-morbidity was present in more than 5% of patients.

**Response:**

Initial assessment by the DMC after the first 100 patients in September 2015 agreed that the randomisation should continue. In February 2017, the DMC performed an outcomes assessment on the LDAC-T versus LDAC arms of the LI-1 trial (n=243), at which point additional randomisations were suspended pending the review. At the second interim analysis in November 2017 after 183 events, while there was a benefit in remission rates, however LDAC-T failed to show a sufficiently promising hazard ratio for survival, and therefore on the recommendation of the DMC the arm was closed. Patients who were benefitting from tosedostat were permitted to stay on treatment. The data presented here represents an analysis undertaken after the DMC recommendation with cleaner data and more mature follow up.

Overall, CR was achieved in 16% of patients with a further 6% achieving a CRi (total ORR 21%). There was a non-significant increase in CR rate with tosedostat (LDAC-T vs LDAC) (19% vs 12%, OR 0.61 (0.30-1.23) p=0.17). For the overall response (CR+CRi), there was little evidence that a benefit of the addition of tosedostat could be seen (25% vs18%; OR 0.68 (0.37-1.27) p=0.22). A non-significant reduction in resistant disease was observed by the addition of tosedostat (60% vs 68% OR 0.68 (0.40-0.16) p=0.16. The thirty-day mortality was not significantly increased (16% vs 14%, HR 1.26 (0.65-2.46) p=0.5. (table 2).;

**Treatment Compliance:** Following remission, treatment was given to 19/22 LDAC patients (5 patients received 1 course, 4 patients 2 courses, 1 patient 3 courses, 2 patients 4 courses, and 7 patients 6 or more courses) and 26/30 Tosedostat patients treated (3 patients received 1 course, 4 patients 2 courses, 6 patient 3 courses, 4 patients 4 courses, 1 patient 5 courses, and 12 patients 6 or more courses). No patient allocated to LDAC alone received tosedostat; however 2 patients randomised to receive LDAC-T received 1 and 3 courses of LDAC alone.

**Overall Survival** The OS did not differ by treatment arm (LDAC-T vs LDAC) (2-year OS 16% vs 12%, HR 0.97 (0.73-1.28) p=0.8; figure 2a).

**Survival of Responders:** For the total52 patients who achieved a CR/CRi, the median OS from remission was 21.8 months. Although there was an apparent modest benefit in 2 years survival from response (447% vs 36%), this failed to reach statistical significance (HR 0.88 (0.43-1.80) p=0.7) (figure 2b). For patients who relapsed, there was no significant difference in the survival following relapse between treatment arms (1 year survival post relapse 30% vs 17%; HR 0.93 (0.45-1.92) p=0.8; (figure 2c). In the patients who did not achieve CR/CRi, the survival was not different between the arms.

**Relapse Free Survival:** Although remission rates were higher in the tosedostat arm, there was no significant difference in duration of remission RFS (HR 0.82 (0.46-1.47) p=0.5; figure 2d).

**Toxicity:** Although rates of grade 3+ toxicity were low overall, tosedostat was associated with significantly increased diarrhoea, and cardiac toxicity (2 grade 4 events that led to tosedostat discontinuation- AF and raised troponin) in course 1, and with greater cardiac and liver alanine transaminase (ALT) toxicity in course 2 . Resource usage (blood product support, antibiotics and hospital utilisation) tended to be consistently higher in the tosedostat arm, though the only significant difference between arms was an increased use of platelets in course 1 (mean 5.0 vs 3.5 pools p=0.006); (figure 3a and 3b).

**Exploratory Subgroup Analysis:**

Exploratory analyses were carried out on survival, to find out if there was an identifiable subgroup with a differential effect of treatment. Baseline covariates including age, sex, diagnosis, cytogenetics, white blood count, performance status, and Wheatley risk group were explored (Supplemental Figure 2). Additional analysis by NPM1 and FLT3-ITD/TKD status was additionally explored. More detailed molecular analyses were not available. Although the power of such analyses is limited by small numbers in some subgroups, there were no significant interactions between baseline variables and treatment for survival. In particular, no subgroup could be identified where there was a benefit for LDAC-T.

**Discussion:**

Compared to younger patients with AML, the decision in treatment strategy is not always obvious. At one end of the spectrum there are patients who have several co-morbidities where even if the prognostic assessment of their disease biology is not adverse, are at high risk of not surviving a version of standard chemotherapy. At the other are patients who are chronologically old but have few co-morbidities combined with good performance status. In these cases intensive chemotherapy may be of benefit, but the decision to offer conventional chemotherapy may be negatively influenced by adverse disease biology, where chemotherapy may have a low chance of success. Some patients who are fit may decline treatment in preference for more time out of hospital, particularly if facilitated by outpatient or oral medication. At the centre of this is the physician – indeed in our previous AML14 trial where an intensive and non-intensive treatment approach were available, the physician emerged as an independent factor in treatment choice. Many prognostic scoring systems have been developed for younger patients to guide treatment decisions, and such scores can be developed for older patients, but few have been prospectively validated in recipients of non-intensive therapy. We developed the Wheatley Score19, which is useful in predicting expected outcomes for non-intensive treatment approaches. In this study based on the Wheatley score 4% of patients were favourable, 31% intermediate and 65% were adverse risk with respective expected 12-month OS 36%, 42% and 14% respectively. The predicted 12 month OS was 25%, which is what was achieved.

We developed LDAC as a standard of care at a time when no other randomised trials in this patient population had suggested an alternative. We found that clinical toxicities were no greater than best supportive care3. However durable benefit was only seen in the 18% of patients who entered CR, where median OS was 575 days compared to only 66 days for those that did not respond. This experience led to the development of a “Pick a Winner” design which depended on an initial improvement in remission rate as a surrogate for future survival benefit. A number of novel treatments that produced encouraging results in unrandomised trials have been included, but failed the scrutiny of randomisation20-23. Others were able to double the remission rates but did not improve overall survival24,25. Another observation has been that in different cohorts of LDAC patients the remission rate varied from 14% to 21% and the 12 month survival from 25% to 32%, without obvious differences in patients’ characteristics26. To date 2480 randomisations have been undertaken in 1753 patients to evaluate 13 agents or combinations21-26. The evaluation is complete on 11 options, and 2 are ongoing. The use of remission as a surrogate endpoint helps identify and exclude unpromising treatments, but should not replace survival as an endpoint in trials in this population.

Mechanistically tosedostat has several properties which could be particularly helpful in older patients8. The developmental phase I/II experience in relapse and in combination was both feasible from the toxicity point of view, and appeared to offer an improved clinical response. The oral formulation is also helpful in the elderly population. We therefore initiated the randomised comparison reported here. Disappointingly, the combination failed to meet the IDMC criteria to continue the trial. In reaching their recommendation the IDMC looked not only at the strict continuation criteria set down, based upon remission, but also relied upon safety data, and in particular early mortality when deciding whether or not to continue. The IDMC closed the tosedostat arm based on a failure to improve survival as assessed by the confidence intervals at the time of their analysis which depended on observing a hazard ratio of 0.69, representing the requirement to improve 2-year survival from 11% to 22%. It was therefore concluded that even with more patients included the drug was unlikely to demonstrate the sort of benefit required by the design of the trial. As is observed in many such studies the primary reason for discontinuation was refractory disease. For responding patients the median OS was an impressive 21.8 months, although we were unable to identify any clinical or laboratory findings which could reliably identify such patients a recent publication by Visani15 has proposed a gene expression profile that could predict such a response and could warrant further evaluation.

The introduction of hypomethylating agents has improved survival without substantially improving the rate of remission4 and globally considered the standard of care for the frail unfit AML patient. New combinations (including venetoclax, enasidenib, ivosidenib and glasdegib) show considerable promise, and indeed have received regulatory approval for this patient group, mostly based on unrandomised data27-31. As described above there are several examples of early promise which fail in the rigour of randomization. Although recently published data from the VIALE-A study, in perhaps a more selected frail elderly AML population, combining venetoclax with azacitidine has demonstrated a significant improvement in overall survival, this combination may ultimately become considered the new standard of care in this setting6.

In conclusion, tosedostat demonstrated promising early data and acceptable tolerability, its addition to LDAC did achieve a modest improvement in response rates, but we did not find evidence that it produced a survival benefit in this group of patients. Strategies other than aminopeptidase inhibition appear to demonstrate more rational approaches for future non intensive combination therapy in AML.

.

**Acknowledgements**

We wish to thank CTI Biopharma for supporting the trial, Blood Cancer UK for research support, and the Haematology Clinical Trials Unit and Centre for Trials Research, Cardiff University for managing the trial.

The following investigators recruited patients to the trial:

**Aalborg University Hospital:** Maria Kallenbach, M Severinsen; **Aberdeen Royal Infirmary:** Dominic Culligan, Caroline Duncan; **Addenbrooke's Hospital:** Pramila Krishnamurthy; **Airedale General Hospital:** Ann Cuthbert, Chetan Patalappa, Michail Spanoudakis; **Arrowe Park Hospital:** David Galvani; **Auckland City Hospital:** I Berkahn, N Patton, Lucy Pemberton; **Barnet Hospital:** Andres Virchis; **Basildon University Hospital:** Parag Jasani; **Beatson West of Scotland Cancer Centre:** Anne Parker; **Belfast City Hospital:** Claire Arnold, Robert Cuthbert, Damien Finnega; **Birmingham Heartlands Hospital:** Manos Nikolousis, Guy Pratt; **Blackpool Victoria Hospital:** Paul Cahalin; **Bradford Royal Infirmary:** Sam Ackroyd; **Bristol Haematology & Oncology Centre:** Priyanka Mehta, Rachel Protheroe; **Capital & Coast DHB (Wellington):** Robert Weinkove; **Castle Hill Hospital (Hull):** Sara Ali; **Chesterfield Royal Hospital:** Emma Welch; **Christchurch Hospital:** Mark Smith, Ruth Spearing; **Churchill Hospital:** Paresh Vyas; **Colchester General Hospital:** Gavin Campbell, Mike Hamblin, Marion Wood; **Conquest Hospital:** Sunil Gupta, Simon Westonsmith; **Countess of Chester Hospital:** Arvind Pillai; **Derriford Hospital (Plymouth):** Hannah Hunter, Simon Rule; **Forth Valley Royal Hospital:** Roderick Neilson; **Gloucestershire Royal Hospital:** Richard Lush; **Huddersfield Royal Infirmary:** Kate Rothwell, Wunna Swe; **Ipswich Hospital:** Isobel Chalmers, Mahesh Prahladan; **Kettering General Hospital:** Mark Kwan, Matthew Lyttleton; **Leicester Royal Infirmary:** Ann Hunter, Alexander M Martin; **Lincoln County Hospital:** Kandeepan Saravanamuttu; **Manchester Royal Infirmary:** Muhammad Saif, Eleni Tholouli; **Medway Maritime Hospital:** Vivienne Andrews; **Middlemore Hospital:** Sharon Jackson, Rajeev Rajagopal; **New Victoria Hospital:** Anne Morrison; **NHS Ayrshire & Arran (Ayr Hospital):** William Gordon; **NHS Lanarkshire:** Lindsay Mitchell; **Northampton General Hospital:** Angela Bowen, Alistair McGrann, Sajjan Mittal; **Northwick Park Hospital:** Nicki Panoskaltsis; **Nottingham University Hospital:** Jenny Byrne, Emma Das-Gupta, Rohini Radia, Nigel Russell; **Palmerston North Hospital:** Bart Baker, Allanah Kilfoyle, Elayne Knottenbelt; **Pilgrim Hospital:** Ciro Rinaldi; **Pinderfields Hospital:** Paul Moreton; **Poole General Hospital:** Darshyani Furby, Fergus Jack; **Queen Alexandra Hospital (Portsmouth):** Charles Alderman, Edward Belsham, Robert Corser, Tanya Cranfield, Helen Dignum, Christopher James; **Queen Elizabeth Hospital, Kings Lynn:** Emma Gudgin; **Queen's Hospital, Romford:** Claire Hemmaway, Mahalakshmi Mohan; **Rigshospitalet:** Peter Kampman, Lars Kjeldsen, Jindrich Mourek, Ove Juul Nielsen, Carsten Utoft Niemann; **Royal Berkshire Hospital:** Henri Grech, Asif Khan, Rebecca Sampson; **Royal Cornwall Hospital:** Desmond Creagh; **Royal Darwin Hospital:** Ferenc Szabo; **Royal Devon & Exeter Hospital:** J Coppell, D Veale; **Royal Free Hospital:** Panagiotis Kottaridis; **Russells Hall Hospital:** Savio Fernandes; **Salisbury District Hospital:** Jonathan Cullis, Effie Grand; **Sandwell Hospital:** Farooq Wandroo; **Singleton Hospital:** Unmesh Mohite; **Southport and Formby District General Hospital:** David O'Brien; **St Helens & Knowsley (Whiston):** Toby Nicholson; **St Richard's Hospital:** Sarah Janes; **Stoke Mandeville Hospital:** Robin Aitchison; **Sunderland Royal Hospital:** Mike Galloway, Susanna Mathew; **The Christie:** Mike Dennis; **The Great Western Hospital:** Norbert Blesing, Sarah Green; **The James Cook University Hospital:** Rajesh Mamadigi, Diane Plews; **The Royal Bournemouth Hospital:** Joseph Chacko; **The Royal Liverpool Hospital:** Rahuman Salim; **The Royal Oldham Hospital:** Allameddine Allameddine, Hayley Greenfield, David Osborne; **Townsville Hospital:** Georgina Hodges, Hock Choong Lai; **Trafford General Hospital:** Patrick Carrington; **University Hospital Aintree:** Walid Sadik, Lynny Yung; **University Hospital Coventry & Warwickshire:** Anand Lokare; **University Hospital of Wales:** Caroline Alvares, Steve Knapper; **Waikato Hospital:** Hugh Goodman, Shahid Islam; **Wycombe Hospital:** Robin Aitchison, Jonathan Pattinson, Beena Pushkaran; **Ysbyty Glan Clywd:** Earnest Heartin; **Ysbyty Gwynedd:** David Edwards, Jim Seale

**References**

1. Kantarjian H, Ravandi F, O’Brien S, Cortes J, Faderl S, Garcia-Manero G et al.Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. *Blood* 2011; 116: 4422–4429.
2. Appelbaum,F.R; Gundacker,H.; Head,D.R et al. Age and acute myeloid leukemia. *Blood* 2008; 107(9), 3481-3285
3. Burnett AK, Milligan D, Prentice, AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. *Cancer*. 2007;109 (6):1114-1124.
4. Fenaux P, Mufti GJ, Hellstrom-Liindberg E, et al. Azacytidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. *J. Clin.Oncol*. 2010, 28: 562 – 569
5. Kantarjian HM, Thomas XG, Dmoszynska A, et al.. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. *J.Clin.Oncol.* 2012;30 (21):2670-2677.
6. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. PMID: 32786187.
7. Reid AH, Protheroe A, Attard G, et al. A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 minopeptidases, in patients with advanced solid tumors. *Clin Cancer Res.* 2009; 15(15):4978-4985
8. Krige D, Needham LA, Bawden LJ, et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. *Cancer Res.* 2008; 68(16):6669-6679.
9. Saric T, Graef CI and Goldberg AL. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. *J. Biol. Chem*.2004, 279: 46723-46732
10. Drummond AH, Farmer H, Flores N, Miles LEC, Callaghan J, Bawden LJ and Krige D. Antiproliferative aminopeptidase inhibitors inhibit mTOR and alter expression of Noxa and Mlc-1in leukemic cells via amino acid deprivation. *AACR Abstract* 2007: 4069
11. Jenkins C, Hewamana S, Krige D, et al. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia. *Leuk Res* 2011;35(5):677-81
12. Löwenberg B1, Morgan G, Ossenkoppele GJ, et al. Phase I/II clinical study of

Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. *J Clin Oncol.* 2010; 28(28):4333-4338

1. Cortes J, Feldman E, Yee K, et al. Two dosing regimens with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. *Lancet Oncol.* 2013; 14(4):354-362
2. Mawad R, Becker PS, Hendrie P, et al. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. *Br J Haematol.* 2016; 172(2):238-245.
3. Visani G, Loscocco F, Fuligini F et al. Tosedostat with Low-Dose Cytarabine combo induces a high rate of responses that can be predicted by genetic prifiling in AML: final results of a phase II multicentre study. *Haematologica* 2015; 100703, p 564
4. Visani G, Loscocco F, Dennis M, Zuffa E, Candoni A, Sensi A, Giannini B, Musuraca G, Mianulli AM, Clavio M, Rocchi M, Gibellini D, Navari M, Gilkes A, Piccaluga PP, Isidori A. Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML. Blood Adv. 2020 Oct 27;4(20):5040-5049.
5. Hills RK, Burnett AK. Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. *Blood*. 2011; 118(9): 2389-94
6. Sorror ML, Giralt S, Sandmaier BM, de Lima M, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. *Blood* 2007; 110: 4606–4613.
7. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. *Br J Haematol* 2009; 145:598–605.
8. Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K et al. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol 2012; 158: 519–522.
9. Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K et al. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 2011; 25: 1122–1127
10. Burnett AK, Russell N, Hills RK, et al. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015;29(6):1312-1319. doi:10.1038/leu.2015.38
11. Dennis M, Russell N, Hills RK, et al. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015;125(19):2923-2932. doi:10.1182/blood-2014-10-608117
12. Burnett, A. K., Hills, R. K., Hunter, A. E.et al, UK National Cancer Research Institute AML Working Group. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. *Leukemia*, 2013; *27*(1), 75-81
13. Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013; 122: 1384–1394
14. Dennis M, Hills R, Russell N, Copland M, Thomas I, McMullin MF, Ali S, Dignum H and Burnett AK An Evaluation of 17 years of Low Dose Cytarabine as Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival and Potential Underutilisation. Blood (2017) 130 (Supplement 1): 3874

27.Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017:doi.10.1182/blood-2017-04-779405.

1. 28DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med 2018;378:2386-98.
2. 29Wei AH, Jr SAS, Hou J-Z, et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. J Clin Oncol 2019;37:1277-84.

30 .DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet Oncology 2018;19:216-28

31. Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dosecytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high risk myelodysplastic syndrome. Leukemia 2019;33:379-389.

**Disclosure of Conflicts of Interest**

AKB was an employee of CTI Biopharma 2015-2017. REC has received research funding and honoraria from Novartis and Bristol Myers Squibb, and honoraria from Pfizer, Jazz Pharmaceuticals and Abbvie. MC has received research funding from Novartis, Bristol-Myers Squibb, Cyclacel and Takeda/Incyte, is/has been an advisory board member for Bristol-Myers Squibb, Novartis, Incyte, Daiichi Sankyo, Jazz and Pfizer and has received honoraria from Astellas, Bristol-Myers Squibb, Novartis, Incyte, Pfizer and Gilead. The other authors have nothing to disclose.

**Author Contributions:** MD: chief investigator; reviewed the data and wrote the manuscriptAKB: designed the trial; wrote protocol; chief investigator until Q3 2014; RKH: designed the trial, wrote the protocol, analysed the data. CA analysed the data with extended follow up, IT supervised the data collection, reviewed the data. MTS, CH, and PG were major recruiters. NHR: designed trial; reviewed the data. MC Co-CI, and REC reviewed the data. All authors reviewed the manuscript.

.